Bicara Therapeutics (BCAX) Expected to Announce Earnings on Tuesday

Key Points

• Bicara Therapeutics is scheduled to announce its Q2 2025 earnings on August 12th, with expectations of posting a loss of ($0.54) per share.
• The stock is currently trading down 0.1% at $11.11, with analysts giving it a consensus rating of "Moderate Buy" and a target price of $31.86.
• AQR Capital Management has recently acquired a new stake in Bicara Therapeutics, purchasing 19,034 shares valued at approximately $248,000.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.28). On average, analysts expect Bicara Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bicara Therapeutics Stock Performance

Shares of BCAX remained flat at $10.20 during mid-day trading on Friday. 194,114 shares of the stock traded hands, compared to its average volume of 326,701. Bicara Therapeutics has a twelve month low of $7.80 and a twelve month high of $28.09. The company has a fifty day simple moving average of $10.43 and a 200 day simple moving average of $11.98.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. HC Wainwright reduced their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Wall Street Zen downgraded shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Wedbush reaffirmed an "outperform" rating and issued a $30.00 target price on shares of Bicara Therapeutics in a report on Friday, May 23rd. Finally, Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 target price for the company in a report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Bicara Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $31.86.

Institutional Trading of Bicara Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of BCAX. Geode Capital Management LLC boosted its holdings in shares of Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company's stock valued at $6,248,000 after purchasing an additional 180,833 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of Bicara Therapeutics by 26.5% in the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company's stock valued at $4,543,000 after purchasing an additional 72,998 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of Bicara Therapeutics in the 1st quarter valued at $248,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.